Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/XPR1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/XPR1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/XPR1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/XPR1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/XPR1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/XPR1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/XPR1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/XPR1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/XPR1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/XPR1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/XPR1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005170133 | Oral cavity | NEOLP | biological process involved in interaction with host | 47/2005 | 203/18723 | 2.42e-07 | 7.85e-06 | 47 |
GO:004671832 | Oral cavity | NEOLP | viral entry into host cell | 36/2005 | 144/18723 | 8.75e-07 | 2.37e-05 | 36 |
GO:005212632 | Oral cavity | NEOLP | movement in host environment | 41/2005 | 175/18723 | 9.99e-07 | 2.67e-05 | 41 |
GO:004440932 | Oral cavity | NEOLP | entry into host | 37/2005 | 151/18723 | 1.05e-06 | 2.79e-05 | 37 |
GO:003166831 | Oral cavity | NEOLP | cellular response to extracellular stimulus | 48/2005 | 246/18723 | 2.80e-05 | 4.32e-04 | 48 |
GO:007149632 | Oral cavity | NEOLP | cellular response to external stimulus | 57/2005 | 320/18723 | 8.00e-05 | 1.01e-03 | 57 |
GO:003166932 | Oral cavity | NEOLP | cellular response to nutrient levels | 42/2005 | 215/18723 | 8.37e-05 | 1.05e-03 | 42 |
GO:003166732 | Oral cavity | NEOLP | response to nutrient levels | 77/2005 | 474/18723 | 1.27e-04 | 1.49e-03 | 77 |
GO:000926731 | Oral cavity | NEOLP | cellular response to starvation | 29/2005 | 156/18723 | 2.17e-03 | 1.42e-02 | 29 |
GO:001603218 | Prostate | BPH | viral process | 147/3107 | 415/18723 | 4.46e-21 | 5.52e-18 | 147 |
GO:001905818 | Prostate | BPH | viral life cycle | 112/3107 | 317/18723 | 2.87e-16 | 5.54e-14 | 112 |
GO:007149618 | Prostate | BPH | cellular response to external stimulus | 102/3107 | 320/18723 | 8.99e-12 | 6.79e-10 | 102 |
GO:005212618 | Prostate | BPH | movement in host environment | 64/3107 | 175/18723 | 1.28e-10 | 7.47e-09 | 64 |
GO:004440318 | Prostate | BPH | biological process involved in symbiotic interaction | 90/3107 | 290/18723 | 6.98e-10 | 3.25e-08 | 90 |
GO:005170118 | Prostate | BPH | biological process involved in interaction with host | 69/3107 | 203/18723 | 9.94e-10 | 4.56e-08 | 69 |
GO:003166817 | Prostate | BPH | cellular response to extracellular stimulus | 79/3107 | 246/18723 | 1.32e-09 | 5.69e-08 | 79 |
GO:004440918 | Prostate | BPH | entry into host | 54/3107 | 151/18723 | 8.66e-09 | 2.96e-07 | 54 |
GO:004671818 | Prostate | BPH | viral entry into host cell | 52/3107 | 144/18723 | 1.11e-08 | 3.68e-07 | 52 |
GO:003166910 | Prostate | BPH | cellular response to nutrient levels | 67/3107 | 215/18723 | 8.51e-08 | 2.12e-06 | 67 |
GO:000926710 | Prostate | BPH | cellular response to starvation | 52/3107 | 156/18723 | 2.24e-07 | 4.89e-06 | 52 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
XPR1 | SNV | Missense_Mutation | | c.101N>G | p.Asp34Gly | p.D34G | Q9UBH6 | protein_coding | deleterious(0.02) | benign(0.3) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
XPR1 | SNV | Missense_Mutation | | c.2077G>A | p.Glu693Lys | p.E693K | Q9UBH6 | protein_coding | deleterious_low_confidence(0.02) | benign(0.257) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
XPR1 | SNV | Missense_Mutation | novel | c.926N>A | p.Ser309Asn | p.S309N | Q9UBH6 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AC-A7VC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
XPR1 | SNV | Missense_Mutation | novel | c.1376G>A | p.Arg459His | p.R459H | Q9UBH6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
XPR1 | SNV | Missense_Mutation | novel | c.1005N>A | p.Phe335Leu | p.F335L | Q9UBH6 | protein_coding | tolerated(1) | benign(0) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
XPR1 | SNV | Missense_Mutation | | c.1832G>A | p.Arg611His | p.R611H | Q9UBH6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A2FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | goserelin | SD |
XPR1 | SNV | Missense_Mutation | rs751223491 | c.1342C>T | p.Arg448Trp | p.R448W | Q9UBH6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
XPR1 | SNV | Missense_Mutation | | c.817C>T | p.Arg273Trp | p.R273W | Q9UBH6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
XPR1 | SNV | Missense_Mutation | | c.2077N>A | p.Glu693Lys | p.E693K | Q9UBH6 | protein_coding | deleterious_low_confidence(0.02) | benign(0.257) | TCGA-EK-A3GN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
XPR1 | SNV | Missense_Mutation | | c.1798N>A | p.Glu600Lys | p.E600K | Q9UBH6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |